Sorafenib, a multikinase inhibitor with potency against FLT3 mutation, has been clinically used to treat FLT3-positive AML patients in various settings, including front-line, relapsed/refractory, and post-transplant maintenance therapy [4]. The gene discussed is FLT3; the disease is acute myeloid leukemia.